Impact of high-dose peginterferon alfa-2a on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

Hepatology

Volumn 50, Issue 4, 2009, Pages 1045-1055

  Roberts, Stuart K ^a   Weltman, Martin D ^b   Crawford, Darrell H G ^c   McCaughan, Geoffrey W ^d   Sievert, William ^e   Cheng, Wendy S ^f   Rawlinson, William ^g   Desmond, Paul V ^h   Marks, Phillipa S ⁱ   Yoshihara, Motoko ^j   Rizkalla, Bishoy ^j   DePamphilis, Jean K ^k   Dore, Gregory J ⁱ  

^a Alfred ^*  (Australia)

^b NEPEAN HOSPITAL   (Australia)

^c GREENSLOPES PRIVATE HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g New South Wales Government   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j Roche Products   (Australia)

^k HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ABNORMAL LABORATORY RESULT; ADULT; AGE; AGED; ALOPECIA; ANEMIA; ANOREXIA; APPETITE; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENDER; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; INSOMNIA; IRRITABILITY; LETHARGY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RACE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION; ASIAN; CAUCASIAN; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; ETHNOLOGY; GENETICS; HEPATITIS C VIRUS; MIDDLE AGED; NEGRO; TREATMENT OUTCOME;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 70350072278     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23130     Document Type: Article

References (21)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Moises D, Marcellin P, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
4. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. HEPATOLOGY 2001;34:1006-1011.
5. Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozza M, et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C. J Hepatol 2004;41:474-481.
6. Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of interferon-alpha induction therapy and ribavirin on chronic hepatitis C infection: a randomized multicentre study. Scand J Gastroenterol 2002;37:226-232.
7. Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU, et al. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002;9:334-339.
8. Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, et al. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naïve chronic hepatitis C patients. A multicentre randomized controlled trial. J Viral Hepat 2003;10:460-466.
9. Di Marco V, Ferraro D, Almasio P, Vaccaro A, Parisi P, Capello M, et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high dose interferon induction. J Viral Hepat 2002;9:354-359.
10. Mimidis K, Papadopoulos VP, Elefsiniotis I, Koliouskas D, Ketikoglou I, Paraskevas E, et al. Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon α-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis 2006;15:213-219.
11. Balciuniene L, Carlsson T, Ambrozaitis A, Reichard O, Weiland O. Hepatitis C virus RNA levels during initial induction or standard interferon therapy: influence of continued treatment on sustained response. Scand J Infect Dis 2003;35:180-185.
12. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-1447.
13. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT. Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. HEPATOLOGY 2001;33:419-423.
14. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-433.
15. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006;43:954-960.
16. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097.
17. Brady DE, An JW, Lawitz EJ, Harrison S. Does induction pegylated interferon alfa-2b in combination with ribavirin enhance the sustained response rates in patients with genotype 1 and 4 chronic hepatitis C: results from a prospective, randomized, multi-center, open-label treatment study [Abstract]. HEPATOLOGY 2008;48(Suppl.):402A.
18. McHutchison JG, Everson GT, Gordon SC, Jacobson I, Kauffman R, McNair L, et al. PROVE1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C [Abstract]. J Hepatol 2008;48(Suppl. 1):S4.
19. Ferenci P, Laferl H, Scherzer T-M, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-458.
20. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. Quantitation of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. HEPATOLOGY 1998;27:1149-1156.
21. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003;38:645-652.